Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Y-Biologics logo — Exploring antibodies, creating novel therapeutics

Y-Biologics

Exploring antibodies, creating novel therapeutics

Founded 2007 Korea South Korea South 6 employees Venture round Total: $30.00B Biotechnology, Health Care

General Information

Company Name Y-Biologics
Founded Year 2007
Location Korea South Korea South
Employees 6
Industries Biotechnology, Health Care
Funding Stage Venture round
Business Model B2B, D2C, API
Revenue Model Service Fee, Licensing, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Y-Biologics. To contact Y-Biologics, visit ybiologics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Y-Biologics compare?

A PDF of Y-Biologics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Y-Biologics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Y-Biologics

Y-Biologics, with the slogan "Exploring antibodies, creating novel therapeutics", stands out as Korea's leading biotechnology company specializing in antibody drug development. Founded in 2007, Y-Biologics has established robust R&D capabilities, focusing on innovative treatments within the fields of immuno-oncology and cytokine therapy. Their proprietary bispecific antibody platform aims to address unmet medical needs by enhancing patient response rates and drug efficacy.

With a comprehensive suite of technologies that includes antibody screening, optimization, and cell line development, Y-Biologics provides a full-cycle approach to drug development. The company's recent venture round on February 24, 2022, raised KRW30.00 billion, with notable backers such as Smilegate Investment, DAYLI Partners, DS Asset Management, Mirae Asset Securities, CJ HealthCare Corp., Kolon Investment, Korea Omega Investment Corp., and Genexine, underscoring strong investor confidence.

Business keywords: Antibody Drug Development, Immuno-Oncology, Cytokine Therapeutics, Bispecific Antibody Platform, Antibody Screening, Protein Expression, Cell Line Development, Human Nanobody Screening, Antibody Humanization, Affinity Maturation, Recombinant Protein Production, Stable Cell Line Development, Antibody Optimization, Hybridoma Sequencing, Global Immuno-Chemotherapeutic Market

Services & Products

Research and Development
Drug Development
Biotechnology Research
Collaborative Innovation

Target Customers

Pharmaceutical Companies Healthcare Providers Biotech Researchers Investors in Life Sciences

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Y KRW30.00B 8
Smilegate Investment DAYLI Partners DS Asset Management
Smilegate Investment, DAYLI Partners +6
24 Feb 2022
Venture Round Y Undisclosed 2
DAYLI Partners IMM Investment
DAYLI Partners, IMM Investment
01 Jan 2018

Y-Biologics Alternatives & Competitors

View All Alternatives
Y-Biologics vs
Biointron
Biointron China

Recombinant Antibody Expression, Delivery in 2 weeks (From Gene Sequence to Purified Antibody)

Series B
41 employees
Biotechnology, Health Care
Compare Y-Biologics vs Biointron
Y-Biologics vs
Creative Biolabs
Creative Biolabs United States

Antibody discovery, antibody engineering.

23 employees
Biotechnology, Health Care
Y-Biologics vs
Xencor
Xencor United States

Proteins by Design

Post-IPO Equity
303 employees
Biotechnology, Health Care
View all alternatives

FAQ About Y-Biologics

Exploring antibodies, creating novel therapeutics
Y-Biologics was founded in 2007.
Y-Biologics is headquartered in Korea South.
Y-Biologics operates in Biotechnology and Health Care. Its work centres on Antibody Drug Development, Immuno-Oncology, Cytokine Therapeutics and Bispecific Antibody Platform. Its customers include Pharmaceutical Companies, Healthcare Providers and Biotech Researchers.
Y-Biologics has a B2B, D2C and API business model. Its revenue comes from Service Fee, Licensing and Project Based.
Y-Biologics has approximately 6 employees.
Y-Biologics has completed 2 funding rounds, raising a total of $30.00B. The latest funding stage is Venture round.
Y-Biologics offers: Research and Development, Drug Development, Biotechnology Research, Collaborative Innovation.
Top alternatives and competitors to Y-Biologics include Biointron, Creative Biolabs, Xencor, Oxford BioTherapeutics, Immunitas Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Y-Biologics and Biointron are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Y-Biologics, https://bouncewatch.com/company/y-biologics, updated 19 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout